← back to search

Shuman Zhen

Hebei Medical University · CN
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Ferroptosis and cancer prognosis, and Circular RNAs in diseases.
h-index
6
citations
184
works
13
NIH funding
primary concept
email

Recent publications

circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis
Molecular Cancer 2024cited by 59position: middledoi
NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence
Cell Death Discovery 2024cited by 33position: firstdoi
Flaxseed Oil Alleviates PFOS-Induced Liver Injury by Regulating Hepatic Cholesterol Metabolism
Journal of Agricultural and Food Chemistry 2024cited by 12position: middledoi
Association between composite dietary antioxidant index and cardiovascular health: Results from two observational studies
Journal of Functional Foods 2024cited by 3position: middledoi
Screening of Differentially Expressed Genes Based on the ACRG Molecular Subtypes of Gastric Cancer and the Significance and Mechanism of AGTR1 Gene Expression
Journal of Personalized Medicine 2023cited by 9position: middledoi
Function of hsa_circ_0006646 as a competing endogenous RNA to promote progression in gastric cancer by regulating the miR-665–HMGB1 axis
Journal of Gastrointestinal Oncology 2023cited by 7position: middledoi
Circular RNA hsa_circ_0002938 (circCRIM1) promotes the progression of esophageal squamous cell carcinoma by upregulating transcription factor 12
Neoplasma 2023cited by 6position: middledoi
Ceruloplasmin is associated with the infiltration of immune cells and acts as a prognostic biomarker in patients suffering from glioma
Frontiers in Pharmacology 2023cited by 5position: middledoi
C1ql4 regulates breast cancer cell stemness and epithelial-mesenchymal transition through PI3K/AKT/NF-κB signaling pathway
Frontiers in Oncology 2023cited by 3position: middledoi
Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer
Journal of Cancer Research and Clinical Oncology 2022cited by 45position: middledoi
Comparison of survival benefits between simultaneous integrated boost intensity-modulated radiotherapy and conventional fractionated radiotherapy for esophageal squamous cell carcinoma
Zhonghua fangshe zhongliuxue zazhi 2018cited by 0position: middledoi
Optimal radiation dose for esophageal squamous cell carcinoma
Zhonghua fangshe zhongliuxue zazhi 2017cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yuqing Duan · Xi'an Medical University4 papers (2023–2024)Jiali Wang · Beijing University of Posts and Telecommunications3 papers (2022–2024)Lihua Liu · Ministry of Education3 papers (2022–2023)Fan Xu · Guangdong University of Technology2 papers (2024–2024)Huanting Pei · Hebei Medical University2 papers (2024–2024)Wei Lv · Chongqing University2 papers (2023–2023)Yueping Liu · Hebei Medical University2 papers (2022–2024)Yunlong Jia · University of California, Irvine2 papers (2023–2024)Lihua Liu · Hebei Medical University2 papers (2023–2024)Tianxu Liu · Peking University2 papers (2023–2024)Jiali Wang · Hebei Medical University2 papers (2023–2024)Xuejiao Ren · Changchun University of Science and Technology2 papers (2017–2018)Chun Han · Hebei Medical University2 papers (2017–2018)Jinshi Zuo · Hebei Medical University2 papers (2024–2024)Yadong Zhang · Hebei Medical University1 papers (2024–2024)Lan Wang · North Sichuan Medical University1 papers (2018–2018)Yuming Wu · Hebei Medical University1 papers (2023–2023)Boyang Zheng · Pennsylvania State University1 papers (2024–2024)Jing Qin · Hong Kong Polytechnic University1 papers (2023–2023)Ping’an Ding · Hebei Medical University1 papers (2023–2023)